Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14347678 | 1.00 | CA1 (0.34) | CA1CA2HDAC7HDAC8HDAC6 | |
| SCHEMBL14347681 | 0.90 | CA2 (0.43) | CA1CA2DPP7CTSSCTSK | |
| SCHEMBL8424736 | 0.90 | CA2 (0.43) | CA1CA2DPP7CTSSCTSK | |
| SCHEMBL13359747 | 0.83 | CA1 (0.34) | CA1CA2HDAC7HDAC8HDAC6 | |
| SCHEMBL14375631 | 0.83 | CA1 (0.34) | CA1CA2HDAC7HDAC8HDAC6 | |
| SCHEMBL8241852 | 0.83 | CA1 (0.34) | CA1CA2HDAC7HDAC8HDAC6 | |
| SCHEMBL14348147 | 0.83 | TDP1 (0.32) | CA1CA2 | |
| SCHEMBL8426466 | 0.83 | PDF (0.33) | — | |
| SCHEMBL14348132 | 0.83 | PDF (0.33) | — | |
| SCHEMBL8426448 | 0.83 | TDP1 (0.32) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7456172-B2 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-07-17 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | PSEN1, APP, GABRA6 | CA1 103/4885CA2 319/4885HDAC7 2527/4885 |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | GABRA5, APP, GABRE | CA1 1100/4885CA2 1991/4885HDAC7 2657/4885 |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BACE1, APH1A, APP | CA1 1397/4885CA2 2765/4885HDAC7 2913/4885 |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | BACE1, APP, GABRE | CA1 811/4885CA2 1815/4885HDAC7 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.